Sou Hu Cai Jing·2026-01-23 12:01Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong performance in the orthopedic medical device sector [2] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2] - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2] - The non-recurring net profit was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2] - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2] - The quarterly net profit attributable to shareholders was 77.06 million yuan, soaring by 531.12% year-on-year [2] - The quarterly non-recurring net profit stood at 74.52 million yuan, an increase of 439.4% year-on-year [2] - The company's debt ratio is reported at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2] - The gross profit margin is noted at 67.27% [2] Market Activity - As of January 23, 2026, the stock closed at 26.91 yuan, with a 1.17% increase [1] - The turnover rate was 0.73%, with a trading volume of 21,200 hands and a transaction amount of 57.25 million yuan [1] - On January 23, the net outflow of main funds was 145,000 yuan, accounting for 0.25% of the total transaction amount [1] - Retail investors saw a net inflow of 3.0137 million yuan, representing 5.26% of the total transaction amount [1] - Over the past 90 days, 8 institutions have rated the stock, all giving a buy rating, with an average target price of 31.7 yuan [2]